

CLARIFICATIONS ON THE REGULATIONS GOVERNING PRINCIPAL AND IDENTICAL DRUG PRODUCTS AS DEFINED UNDER ADMINISTRATIVE ORDER NO. 2005-0031

Read online (full-text search, related cases, audio case brief): <https://batas.org/library/d76b32b62c1c/>

Adopted: 21 January 2015

Date Filed: 03 February 2015

Administrative Order No. 2005-0031, “Guidelines and Procedure for the Issuance of the Principal Certificate of Product Registration and the Listing of Identical Drug Products based on the Identity of Manufacturer and Pharmaceutical Formulation”, was issued to address concerns of unnecessary duplication of technical dossier evaluation in relation to the registration of identical drug products, defined as having identical drug formulation and manufacturer/source of finished product with that of the principal product. This led to the opening of an alternative pathway for registration of these products via listing with significantly reduced requirements based on the assumption that the safety, efficacy, and quality aspects of principal products have been thoroughly assured. Thus, the concepts of Principal Certificate of Product Registration (PCPR) and Certificate of Listing of Identical Drug Product (CLIDP) were established.

Identical drug formulation is defined as having the same name(s) and amount(s) of active medicinal ingredients per dosage unit, excipients, components, and manufacturing process as that of the principal product.

During the implementation of the abovementioned regulation, technical issues with regard to the “similarity” of the principal and the identical drug products were identified. It is in this context that this regulation is issued.

For the clarification of all marketing authorization holders (MAHs) and applicants of principal and identical drug products, FDA hereby reiterates that an identical drug formulation as defined above must be complied with for all principal and identical drug products (e.g. color, scoring, imprints, embossed/ debossed, among others should be uniform for both principal and identical drug products; branded principal products cannot reflect the brand name or any markings identifiable/synonymous to the brand name on the tablet/capsule surface to avoid misbranding of identical drug products).

Incoming applications for CLIDP starting 30 November 2014 must ensure compliance with the abovementioned provisions; otherwise, these applications shall be denied outright and shall be advised to apply for full registration (i.e. a regular Certificate of Product Registration [CPR] in accordance with existing rules and regulations).

Any previously approved CLIDPs are required to apply for the appropriate variation (e.g. change of capsule color) to be identical with the principal product prior to or during the renewal of their respective authorizations. Likewise, principal products bearing the brand name or any markings identifiable/ synonymous to the brand name on the tablet/capsule surface are required to apply for appropriate variation. Application for variation shall be until 30 March 2015; failure to comply shall mean disapproval of renewal applications and subsequent withdrawal from the market.

For your information and strict compliance.

(SGD) ATTY. NICOLAS B. LUTERO III, CESO III

Assistant Secretary of Health
OIC, Food and Drug Administration

ABOUT BATAS.ORG

Study smarter at BATAS.org

The Philippine bar review and law-school companion built around how your brain actually remembers.

The complete Philippine law library - free for everyone.

More than 100,000 Supreme Court decisions, Republic Acts, and executive issuances - full-text searchable, browsable by category and year, and always free. No paywall, no login. This PDF came from it.

Audio case-brief lectures.

Any decision becomes a podcast-style lecture - facts, issues, ruling, and doctrine - with read-along highlighting and a hands-free presentation mode. Study while commuting, working out, or resting your eyes.

Bar review built on the science of memory.

Complete, sequenced courses for all eight bar subjects, narrated like podcasts and reinforced with retrieval practice and spaced review - the study techniques with the strongest evidence behind them.

The full law-school curriculum.

One subscription unlocks the entire J.D. curriculum - every subject, every lesson, with your progress tracked down to the paragraph so you can pick up exactly where you left off, on any device.

Mock exams that tell you where you stand.

Timed multiple-choice exams graded instantly, with per-subject score breakdowns and focus suggestions that point you at your weakest topics first.

A study planner that keeps you on pace.

Set your schedule and BATAS tells you every day whether you are on track for bar day - and exactly which lesson to take next.

Start free at <https://batas.org>

The law library is free forever - and your first lesson is one click away.

The text of this document is an official public record and remains in the public domain. Formatting, presentation, and compilation © 2026 batas.org.

Downloaded free from the batas.org Law Library. Share it freely - the library is free for every law student, bar reviewee, and practitioner.